Quantcast

For The Second-Line Treatment of HER2-Positive Metastatic Breast Cancer, A Targeted Treatment That Increases Progression-Free Survival Relative to Tykerb/Tyverb and Xeloda Would Earn Similar Patient Share in the U.S. and Europe

February 1, 2010

WALTHAM, Mass., Feb. 1 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the second-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, a targeted treatment that increases the median progression-free survival relative to a regimen of GlaxoSmithKline/Nippon Kayaku’s Tykerb/Tyverb and Roche/Chugai’s Xeloda would earn similar patient share in the U.S. and Europe. Surveyed U.S. oncologists would prescribe such a therapy to 50 percent of their second-line HER2-positive metastatic breast cancer patients. Similarly, in Europe, such an agent would earn 40 percent patient share, according to surveyed European oncologists.

“While a drug’s effect on overall survival and progression-free survival are the attributes that most influence surveyed oncologists’ prescribing decisions for the second-line treatment of HER2-positive metastatic breast cancer, surveyed oncologists have realistic expectations for new therapies on these measures. As the HER2-positive segment of the breast cancer market is set to become more crowded with new agents such as Roche’s trastuzumab-DM1 (T-DM1), Pfizer’s neratinib and Roche/Chugai’s pertuzumab, all forecast to launch before 2018, uptake will rely on providing meaningful improvements in overall survival and progression-free survival,” stated Decision Resources Analyst Regina Jammen, M.S.

The new report entitled Metastatic HER2-Positive Breast Cancer: KOLs and Surveyed Oncologists Maintain Strong Enthusiasm for T-DM1 as an Important Second-Line Treatment for HER2-Positive Breast Cancer also finds that T-DM1 earns Decision Resources’ proprietary clinical gold standard status for the second-line treatment of HER2-positive metastatic breast cancer in 2013 and 2018, following its approval in 2011 for third-line treatment of HER2-positive metastatic breast cancer (2013 approval for second-line treatment). T-DM1 has competitive advantages in efficacy and safety relative to a regimen of Tykerb/Tyverb and Xeloda.

About the Report

Metastatic HER2-Positive Breast Cancer: KOLs and Surveyed Oncologists Maintain Strong Enthusiasm for T-DM1 as an Important Second-Line Treatment for HER2-Positive Breast Cancer is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    Decision Resources                        Decision Resources, Inc.
    Gisselle Morales                          Christopher Comfort
    781-296-2691                              781-296-2597
    gmorales@dresources.com                   ccomfort@dresources.com

SOURCE Decision Resources


Source: newswire



comments powered by Disqus